GoAI
Get started
Chordia Therapeutics Inc. logo

Chordia Therapeutics Inc.

190A.T

JPXHealthcareBiotechnology

Open in GoAI

Latest quote

¥81.00

−¥1.00 · -1.22%

Aug 24, 12:46 PM JSTData delayed

190A.T company overview

Regular session · JST · Market data may be delayed.

Company profile

Company website

Chordia Therapeutics Inc., a biotech company, engages in research and development of anti-cancer drugs that targets RNA deregulation stress in Japan. It develops CLK CTX-712, a CLK inhibitor, which is Phase 1 clinical trial for the treatment of relapsed or refractory malignant cancers.; CTX-177, a small-molecule inhibitor of MALT1; CDK12 inhibitor CTX-439; and GCN2 inhibitor CRD-1968099. Chordia Therapeutics Inc. was incorporated in 2017 and is based in Fujisawa, Japan.

Industry
Biotechnology
Sector
Healthcare
Headquarters
JP
CEO
Hiroshi Miyake
Listed since
Jun 14, 2024
Employees
20

Market position

Day range

Current ¥81.00

52-week range

Current ¥81.00

Open
¥81.00
Previous close
¥82.00
Volume
260.4K
0.31× average
Average volume
827.09K
Average daily volume
Market cap
6.09B JPY
Beta
3.14
Market reference 1
50-day average
¥78.28
+3.47% above average
200-day average
¥110.31
-26.57% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
9.8B JPY
P/E (TTM)
-4.04×
P/B (TTM)
2.61×
P/S (TTM)
0×
EV / EBITDA
-5.48×
Earnings yield
-14.46%
Free cash flow yield
-14.92%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-73.28%
Return on assets
-66.60%
Return on invested capital
-73.44%

Financial health

Debt / equity
0×
Current ratio
10.92×
Altman Z-score
13.31
Piotroski F-score
0 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Operating marginNet margin
Gross, operating, and net margin trends17%-16%-49%-82%Operating margin, FY2021: -73.46%Operating margin, FY2023: 8.48%Net margin, FY2021: -65.89%Net margin, FY2023: 8.93%FY2021FY2022FY2023FY2024FY2025
Operating margin FY2021 -73.46%. Operating margin FY2023 8.48%. Net margin FY2021 -65.89%. Net margin FY2023 8.93%.

Income trends

Revenue

2.5B JPY+212.50%

Operating income

−1.79B JPY+0.64%

Net income

−1.79B JPY+2.26%
Income trends across reported periods2.93B JPY1.2B JPY−540.88M JPY−2.28B JPYRevenue, FY2021: 800M JPYRevenue, FY2023: 2.5B JPYOperating income, FY2021: −587.67M JPYOperating income, FY2022: −1.84B JPYOperating income, FY2023: 212.06M JPYOperating income, FY2024: −1.8B JPYOperating income, FY2025: −1.79B JPYNet income, FY2021: −527.11M JPYNet income, FY2022: −1.78B JPYNet income, FY2023: 223.34M JPYNet income, FY2024: −1.83B JPYNet income, FY2025: −1.79B JPYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 800M JPY. Revenue FY2023 2.5B JPY. Operating income FY2021 −587.67M JPY. Operating income FY2022 −1.84B JPY. Operating income FY2023 212.06M JPY. Operating income FY2024 −1.8B JPY. Operating income FY2025 −1.79B JPY. Net income FY2021 −527.11M JPY. Net income FY2022 −1.78B JPY. Net income FY2023 223.34M JPY. Net income FY2024 −1.83B JPY. Net income FY2025 −1.79B JPY.
Metric (JPY)FY2025FY2024FY2023FY2022FY2021
Revenue——2.5B JPY—800M JPY
Cost of goods sold1.43B JPY4.1M JPY6.04M JPY3.15M JPY—
Gross profit−1.43B JPY−4.1M JPY2.49B JPY−3.15M JPY—
Research and development1.43B JPY1.5B JPY2B JPY1.66B JPY1.22B JPY
Selling, general, and administrative309.07M JPY297.51M JPY285.08M JPY184.85M JPY170.74M JPY
Operating expenses364.47M JPY1.8B JPY2.28B JPY1.84B JPY1.39B JPY
Depreciation and amortization2.7M JPY4.1M JPY6.04M JPY3.15M JPY700K JPY
Operating income−1.79B JPY−1.8B JPY212.06M JPY−1.84B JPY−587.67M JPY
Net income−1.79B JPY−1.83B JPY223.34M JPY−1.78B JPY−527.11M JPY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-14.45

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-3.6-7.49-11.38-15.27Q4 '24Q1 '25Q2 '25Q2 '25Q3 '25Q1 '26Q2 '26Q3 '26
Q4 2024, reported Oct 11, 2024: actual -9.6, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Jan 14, 2025: actual -9.07, estimate —, surprise —, Comparison unavailable. Q2 2025, reported Apr 11, 2025: actual -5.25, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 31, 2025: actual -6.13, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 31, 2025: actual -5.6, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Jan 14, 2026: actual -4.24, estimate —, surprise —, Comparison unavailable. Q2 2026, reported Apr 14, 2026: actual -4.71, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Jul 15, 2026: actual -14.45, estimate —, surprise —, Comparison unavailable.

190A.T peers

Chugai Pharmaceutical Co., Ltd. logo

4519.T

Chugai Pharmaceutical Co., Ltd.

¥7,009

-0.03%

Takeda Pharmaceutical Company Limited logo

4502.T

Takeda Pharmaceutical Company Limited

¥5,814

+0.87%

HOYA Corporation logo

7741.T

HOYA Corporation

¥25,000

+0.42%

Otsuka Holdings Co., Ltd. logo

4578.T

Otsuka Holdings Co., Ltd.

¥12,285

+0.74%

Daiichi Sankyo Company, Limited logo

4568.T

Daiichi Sankyo Company, Limited

¥2,866.5

+1.16%

Astellas Pharma Inc. logo

4503.T

Astellas Pharma Inc.

¥2,396.5

+0.40%

Continue in GoAI

Research 190A.T

research.disclaimer